Business UpdateJun 18, 2026, 08:06 AM
TransCode Therapeutics Presents Oncology Pipeline and Strategy
AI Summary
TransCode Therapeutics, Inc. has released a presentation outlining its three-platform oncology strategy. The company is advancing its lead candidate, TTX-MC138, in Phase 2a trials for advanced cancers. Other pipeline assets include the cancer vaccine Seviprotimut-L, the oncolytic virus UIO-524, and RNAi-based therapeutics like TTX-siPD-L1 and TTX-RIGA. The presentation also details recent corporate financing and investment activities, including a $25 million investment from CK Life Sciences.
Key Highlights
- TransCode Therapeutics posted a presentation detailing its three-platform oncology approach.
- The company is advancing TTX-MC138, an antagomiR targeting microRNA-10b, with a Phase 2a trial ongoing for relapsed refractory solid tumors.
- Seviprotimut-L, a cancer vaccine for melanoma, has Orphan Drug status and completed an adaptive Phase 3 trial.
- UIO-524, a next-generation oncolytic virus, is in preclinical development with a focus on bladder cancer.
- TTX-siPD-L1 is an RNAi-based checkpoint inhibitor showing robust preclinical response in pancreatic tumors.
- TTX-RIGA is a PRR agonist designed for tumor-targeted activation to enhance immune response.
- The company has a tunable drug design engine for developing nucleic acid-based therapeutics.
- Recent corporate developments include a $25 million investment from CK Life Sciences and licensing of an immuno-oncolytic portfolio.
Price Impact
More from RNAZ